| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4005330 | American Journal of Ophthalmology | 2008 | 15 Pages |
Abstract
Ranibizumab administered monthly for three months and then quarterly provided significant VA benefit to patients with AMD-related subfoveal CNV and was well tolerated. The incidence of serious ocular or nonocular adverse events was low.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Carl D. Regillo, David M. Brown, Prema Abraham, Huibin Yue, Tsontcho Ianchulev, Susan Schneider, Naveed Shams, The PIER Study Group The PIER Study Group,